Dr. Christopher Bull Granger is a distinguished cardiologist and leading authority in cardiovascular clinical research at Duke University. He currently serves as the Fred Cobb, M.D. Distinguished Professor of Medicine and Professor in the School of Nursing at Duke University, while also maintaining his membership in the Duke Clinical Research Institute. As Director of the Cardiac Care Unit at Duke University Hospital, he oversees critical cardiac care services and patient management protocols. His dual appointment in both the School of Medicine and School of Nursing reflects his commitment to interdisciplinary cardiovascular care and research.
Dr. Granger's primary research focus centers on the conduct and methodology of large randomized clinical trials in heart disease, with particular expertise in acute myocardial infarction and heart failure treatments. He has coordinated the Duke Clinical Research Institute's activities in numerous landmark clinical trials that have shaped contemporary cardiovascular medicine practice guidelines. With over 200 peer-reviewed publications to his name, his scholarly contributions have significantly influenced evidence-based approaches to cardiac care. His work has been instrumental in establishing rigorous methodological standards for clinical trials that evaluate novel cardiovascular therapies and interventions.
Beyond his research achievements, Dr. Granger serves as Associate Editor of the American Heart Journal and sits on the editorial boards of both the Journal of the American College of Cardiology and the European Heart Journal. He is an active Fellow of both the American College of Cardiology and the European Society of Cardiology, regularly contributing to major cardiovascular conferences including the ESC Congress series. His leadership in cardiovascular clinical trials continues to shape the field's methodological approaches and training standards for the next generation of clinical researchers. Dr. Granger remains at the forefront of advancing evidence-based cardiovascular medicine through his ongoing commitment to rigorous clinical trial design and implementation.
